H.C. Wainwright lowered the firm’s price target on Greenwich LifeSciences to $36 from $38 and keeps a Buy rating on the shares after the company provided an update on the Phase 3 FLAMINGO-01 trial.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GLSI:
- Greenwich LifeSciences Reports Progress in Flamingo-01 Trial
- Greenwich LifeSciences provides update on Phase III clinical trial Flamingo-01
- Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue